• Highlights from ASCO Annual Meeting 2024, Leukemia Edition

  • Jun 19 2024
  • Length: 11 mins
  • Podcast

Highlights from ASCO Annual Meeting 2024, Leukemia Edition

Listen for free

View show details

  • Summary

  • In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 ASCO Annual Meeting with a focus on leukemia, as well as Healio’s top headlines from the meeting.

    Jorge E. Cortes, MD, discusses how asciminib demonstrated superior efficacy to standard first-line therapies for certain patients with newly diagnosed chronic myeloid leukemia. :27

    Oreofe O. Odejide, MD, MPH, highlights the importance of this study. 3:30

    Read the full coverage here:

    https://www.healio.com/news/hematology-oncology/20240531/asciminib-may-transform-treatment-paradigm-for-chronic-myeloid-leukemia

    New approach ‘redefining what is a suitable donor’ for stem cell transplant

    Source: Al Malki MM, et al. Abstract 6503. Presented at: ASCO Annual Meeting; May 30 – June 4, 2024; Chicago.

    Disclosures:

    Cortes reports research funding to his institution from or consultant/advisory roles with Gilead Sciences, Jazz Pharmaceuticals, Novartis, Pfizer, Takeda and other companies.
    Show more Show less
Show more Show less

What listeners say about Highlights from ASCO Annual Meeting 2024, Leukemia Edition

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available